GlassScriptPhysician profile
Jessica White
NPI 1386324689
$1,332.75
in general payments reported to CMS, 2019-2025
16 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $146 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $400.04 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $228.98 | 2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $138.95 | 2024-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $128.10 | 2024-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Alkermes, INC. | $100.75 | 2024-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $73.67 | 2025 | Auvelity |
| Lundbeck LLC | $49.11 | 2025 | Rexulti |
| Almatica Pharma LLC | $41.00 | 2025 | Loreev Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.81 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $28.37 | 2025 | Uzedy |
| Idorsia Pharmaceuticals US INC | $24.73 | 2025 | Quviviq |
| Ironshore Pharmaceuticals INC. | $21.71 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $18.54 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $17.40 | 2025 | Qelbree |
| Neos Therapeutics, LP | $16.57 | 2025 | Adzenys Xr-Odt |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $15.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.